ReviewFrontiers in oncology2024

BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges.

Laetitia Collet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.